New approaches aimed for the development of disease modifying therapies of Alzheimer’s disease and other dementia diseases

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| NFS-01-1| The pathological link of glia activation with amyloid clearance in Alzheimer disease | Taisuke Tomita  
Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences,  
The University of Tokyo, Japan |
| NFS-01-2| Principles of Inflammasome Priming and Inhibition: Implications for Neurodegenerative Disorders | Giulio M. Pasinetti  
Icahn School of Medicine at Mount Sinai, USA / James J Peters Veterans Affairs Medical Center, USA |
| NFS-01-3| HMW Aβ oligomers are important targets for disease modifying approach of Alzheimer’s disease | Kenjiro Ono  
Division of Neurology, Department of Medicine, School of Medicine, Showa University, Japan |
| NFS-01-4| canceled                                                                 |                                                                                                                                         |
Original discovery and therapy for SCA from Japan to the world

Chairs: Yoshitaka Nagai
Department of Neurotherapeutics, Osaka University Graduate School of Medicine
Kinya Ishikawa
The Center for Personalized Medicine for Healthy Aging, Tokyo Medical and Dental University

**NFS-02-1** Pathogenesis of spinocerebellar ataxia type 31 (SCA31)

Kinya Ishikawa
The Center for Personalized Medicine for Healthy Aging, Tokyo Medical and Dental University, Japan

**NFS-02-2** Current clinical characteristics of Asidan (SCA36)

Yasuyuki Ohta
Department of Neurology, Okayama University, Japan

**NFS-02-3** Development of disease-modifying therapy for polyglutamine-linked SCA

Yoshitaka Nagai
Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Japan

**NFS-02-4** Antisense oligonucleotide therapy in spinocerebellar ataxia type 3 (SCA3) / Machado-Joseph disease

Henry L. Paulson
University of Michigan, USA
| NFS-03-1 | Antibody-based Therapeutic strategies for ALS targeting misfolded proteins  
Makoto Urushitani  
Department of Neurology, Shiga University of Medical Science, Japan |
|---|---|
| NFS-03-2 | Disruption of RNA metabolism in neurodegenerative diseases and emerging therapeutic strategies  
Clotilde Lagier-Tourenne  
Sean M. Healey & AMG Center for ALS at the Massachusetts General Hospital, USA / Harvard Medical School, USA |
| NFS-03-3 | Glia-immune communication in ALS  
Koji Yamanaka  
Department of Neuroscience and Pathobiology, RIEM, Nagoya University, Japan |
| NFS-03-4 | TDP-43 facilitates exocytosis: unexpected link between ALS and diabetes  
Masahisa Katsuno  
Department of Neurology, Nagoya University Graduate School of Medicine, Japan |